Jiangsu Gdk Biological Technology Co., Ltd (SHA:688670)
China · Delayed Price · Currency is CNY 19.15
+0.75 (4.08%)
At close: Mar 6, 2026
SHA:688670 Revenue
In the year 2025, Jiangsu Gdk Biological Technology had annual revenue of 113.23M CNY with 40.13% growth. Jiangsu Gdk Biological Technology had revenue of 38.57M in the quarter ending December 31, 2025, a decrease of -7.95%.
Revenue
113.23M
Revenue Growth
+40.13%
P/S Ratio
20.84
Revenue / Employee
250.51K
Employees
449
Market Cap
2.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 113.23M | 32.43M | 40.13% |
| Dec 31, 2024 | 80.80M | -53.79M | -39.96% |
| Dec 31, 2023 | 134.59M | -183.89M | -57.74% |
| Dec 31, 2022 | 318.49M | -73.79M | -18.81% |
| Dec 31, 2021 | 392.27M | -196.83M | -33.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Hubei Goto Biopharm | 626.28M |
| Sailong Pharmaceutical Group | 244.84M |
| Shanghai Serum Bio-Technology | 196.21M |